|
Volume 2, Number 4, Supplement 3 (July/August 2005) | ||||
| Recent Progress in Chemotherapy for Colon Cancer Howard A. Burris III, MD Guest Editor |
||||
Contents |
||||
3 |
About this CME activity
|
|||
4 |
Recent progress in chemotherapy for colon cancer: the X-ACT and TREE trials For many years, adjuvant therapy with 5-fluorouracil (5-FU) and leucovorin (LV) has been the mainstay of treatment for patients with stage III colorectal cancer. The results of the X-ACT trial demonstrate that capecitabine, a prodrug of 5-FU, is not only at least as effective as 5-FU/LV in the adjuvant setting but also offers improved tolerability and the convenience of oral administration. The TREE trials, an ongoing evaluation of oxaliplatin with capecitabine or 5-FU/LV, with (TREE-2) and without (TREE-1) bevacizumab, as first-line therapy for metastatic disease, are already yielding results that promise new hope for the tens of thousands of patients who are diagnosed each year with advanced colon cancer.
|
|||
11 |
Widening choices for patients with colon cancer The Sarah Cannon Cancer Center, Nashville, TN The X-ACT trial supports the notion that not only is oral capecitabine an alternative to 5-fluorouracil for adjuvant chemotherapy of colon cancer but, in many ways, may be superior. The TREE trials indicate that prolonged exposure to a thymidylate synthase inhibitor offers an advantage over bolus administration and that bevacizumab can be safely added to increase activity for first-line treatment. These trials provide much useful comparative information that both the oncologist and the patient with colon cancer will want to share with regard to the toxicities and efficacy of these greatly different regimens.
|
|||
12 |
The community oncologists’ perspective CancerCenters of the Carolinas–Eastside, Greenville, SC Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI Louisiana Oncology Associates, Lafayette, LA Three community oncologists who have applied the results of the X-ACT and TREE trials and put them into clinical practice share their candid experiences.
|
|||
15 |
CME post test
|
|||
16 |
CME answer sheet and evaluation
|
|||
Supported by an unrestricted educational grant from Roche Oncology |
||||
© 2005 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||
56 kb